Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AUTL |
---|---|---|
09:32 ET | 10484 | 3.5 |
09:34 ET | 14106 | 3.47 |
09:36 ET | 200 | 3.455 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Autolus Therapeutics PLC | 925.8M | -2.9x | --- |
Cassava Sciences Inc | 925.5M | -16.5x | --- |
Cullinan Therapeutics Inc | 946.4M | -5.2x | --- |
Tyra Biosciences Inc | 892.1M | -10.1x | --- |
Enliven Therapeutics Inc | 1.0B | -11.0x | --- |
Rapport Therapeutics Inc | 830.3M | -16.1x | --- |
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $925.8M |
---|---|
Revenue (TTM) | $10.5M |
Shares Outstanding | 266.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.10 |
EPS | $-1.21 |
Book Value | --- |
P/E Ratio | -2.9x |
Price/Sales (TTM) | 88.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,670.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.